Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 3/20 | 0.52 |
| ▸ | HTR7 | P34969 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 7/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 7/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 6/20 | 0.46 |
| ▸ | DRD4 | P21917 | 3/20 | 0.46 |
| ▸ | FAAH | O00519 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 3/20 | 0.44 |
| ▸ | DRD3 | P35462 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6196310 | 0.89 | DRD2 (0.45) | HTR1AHTR7ADRA1AADRA1BADRA1D | |
| SCHEMBL6192022 | 0.82 | NPC1 (0.67) | HTR1AHTR7ADRA1AADRA1BADRA1D | |
| SCHEMBL12962208 | 0.79 | NPC1 (0.61) | HTR1AHTR7ADRA1AADRA1BADRA1D | |
| SCHEMBL6195674 | 0.77 | MAPK1 (0.53) | HTR1AHTR7ADRA1AADRA1BADRA1D | |
| SCHEMBL17289123 | 0.76 | FAAH (0.65) | HTR1AHTR7DRD4FAAH | |
| SCHEMBL1331198 | 0.76 | FAAH (0.65) | HTR1AHTR7DRD4FAAH | |
| SCHEMBL24712880 | 0.73 | DRD2 (0.59) | ADRA1AADRA1BADRA1DDRD4DRD2 | |
| SCHEMBL6584608 | 0.72 | FAAH (0.60) | HTR1AHTR7DRD4FAAHCYP3A4 | |
| SCHEMBL6771682 | 0.72 | ADRA1A (0.60) | HTR1AADRA1AADRA1BADRA1DDRD2 | |
| SCHEMBL7835709 | 0.72 | ADRA1A (0.60) | HTR1AADRA1AADRA1BADRA1DDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1432701-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS OF THE URINARY TRACT | RECORDATI IRELAND LTD (IE) | 2005-12-21 | — | — | EP | disclosed |
| US-20030181446-A1 | Novel N-acylated heterocycles | RECORDATI S.A. | 2003-09-25 | — | — | US | disclosed |
| US-20030162777-A1 | Novel N-acylated heterocycles | RECORDATI S.A. | 2003-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162777-A1 | Novel N-acylated heterocycles | HTR1A, HTR1D, HTR1E | HTR1A 1/4885HTR7 9/4885ADRA1A 36/4885 |
| US-20030181446-A1 | Novel N-acylated heterocycles | HTR1A, HTR1E, HTR2C | HTR1A 1/4885HTR7 10/4885ADRA1A 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.